Isatuximab, Plus Bortezomib, Lenalidomide, and Dexamethasone (VRd) for Newly Diagnosed Multiple Myeloma (NDMM) Transplant-ineligible Patients: Frailty Subgroup Analysis of IMROZ

被引：0

作者：

Manier, Salomon ^{[1
]}

Dimopoulos, Meletios-Athanasios ^{[2
]}

Leleu, Xavier ^{[3
]}

Moreau, Philippe ^{[4
]}

Cavo, Michele ^{[5
]}

Goldschmidt, Hartmut ^{[6
]}

Orlowski, Robert Z. ^{[7
]}

Tron, Muriel ^{[8
]}

Tekle, Christina ^{[8
]}

Bregeault, Marie-France ^{[9
]}

Shafer, Andrea ^{[8
]}

Beksac, Meral ^{[10
]}

Facon, Thierry ^{[11
]}

机构：

[1] Univ Hosp Ctr Lille, Dept Hematol, Lille, France

[2] Univ Athens, Sch Med, Athens, Greece

[3] CHU Poitiers, Poitiers, France

[4] Univ Hosp Hotel Dieu, Hematol Dept, Paris, France

[5] Univ Bologna, IRCCS Azienda Osped Univ Bologna, Ist Ematol Seragnoli, Bologna, Italy

[6] Univ Hosp Heidelberg, Dept Internal Med 5, GMMG Study Grp, Heidelberg, Germany

[7] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[8] Sanofi, Baltimore, MD USA

[9] Sanofi, R&D, Vitry Sur Seine, France

[10] Istinye Univ, Ankara Liv Hosp, Ankara, Turkiye

[11] Univ Lille, CHU Lille, Serv Malad Sang, Lille, France

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-426

引用

页码：S290 / S291

页数：2